Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock TopplesInvestors Business Daily • 02/03/23
Regeneron stock rallies after profit and revenue beat expectations by wide marginsMarket Watch • 02/03/23
Regeneron Reports Fourth Quarter and Full Year 2022 Financial and Operating ResultsGlobeNewsWire • 02/03/23
Press Release: Dupixent® (dupilumab) approved by European Commission as the first and only targeted medicine indicated for eosinophilic esophagitisGlobeNewsWire • 01/30/23
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic EsophagitisGlobeNewsWire • 01/30/23
Regeneron, Sanofi's Dupixent is one step closer to approval for young children in EuropeMarket Watch • 01/27/23
Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitisGlobeNewsWire • 01/27/23
Dupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP to Treat Children as Young as Six Months Old with Severe Atopic DermatitisGlobeNewsWire • 01/27/23
Top 40 High School Scientists Selected as Finalists in the Regeneron Science Talent Search, the Nation's Oldest and Most Prestigious Science and Math CompetitionPRNewsWire • 01/24/23
Regeneron Pharmaceuticals, Inc. (REGN) 41st Annual J.P. Morgan Healthcare Conference (Transcript)Seeking Alpha • 01/10/23
Regeneron to Report Fourth Quarter and Full Year 2022 Financial and Operating Results and Host Conference Call and Webcast on February 3, 2023GlobeNewsWire • 01/03/23